Welcome to LookChem.com Sign In|Join Free

CAS

  • or
Ethyl (1R,4S,6S)-7-oxabicyclo[4.1.0]heptane-4-carboxylate is a bicyclic ester compound characterized by its unique seven-membered ring structure containing both oxygen and carbon atoms. The presence of the ethyl group and carboxylate functional group classifies it as an ester. The stereochemistry of the molecule is defined by the (1R,4S,6S) configuration, which specifies the arrangement of its chiral centers. This complex and specific structure may endow the compound with potential applications in various fields, such as pharmaceuticals, agrochemicals, or materials synthesis.

365997-31-5 Suppliers

Post Buying Request

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • 365997-31-5 Structure
  • Basic information

    1. Product Name: ethyl (1R,4S,6S)-7-oxabicyclo[4.1.0]heptane-4-carboxylate
    2. Synonyms: ethyl (1R,4S,6S)-7-oxabicyclo[4.1.0]heptane-4-carboxylate;(1S,3S,6R)-7-Oxabicyclo[4.1.0]heptane-3-carboxylic acid ethyl ester
    3. CAS NO:365997-31-5
    4. Molecular Formula: C9H14O3
    5. Molecular Weight: 170.21
    6. EINECS: N/A
    7. Product Categories: N/A
    8. Mol File: 365997-31-5.mol
  • Chemical Properties

    1. Melting Point: N/A
    2. Boiling Point: N/A
    3. Flash Point: N/A
    4. Appearance: /
    5. Density: N/A
    6. Refractive Index: N/A
    7. Storage Temp.: N/A
    8. Solubility: N/A
    9. CAS DataBase Reference: ethyl (1R,4S,6S)-7-oxabicyclo[4.1.0]heptane-4-carboxylate(CAS DataBase Reference)
    10. NIST Chemistry Reference: ethyl (1R,4S,6S)-7-oxabicyclo[4.1.0]heptane-4-carboxylate(365997-31-5)
    11. EPA Substance Registry System: ethyl (1R,4S,6S)-7-oxabicyclo[4.1.0]heptane-4-carboxylate(365997-31-5)
  • Safety Data

    1. Hazard Codes: N/A
    2. Statements: N/A
    3. Safety Statements: N/A
    4. WGK Germany:
    5. RTECS:
    6. HazardClass: N/A
    7. PackingGroup: N/A
    8. Hazardous Substances Data: 365997-31-5(Hazardous Substances Data)

365997-31-5 Usage

Uses

Used in Pharmaceutical Industry:
Ethyl (1R,4S,6S)-7-oxabicyclo[4.1.0]heptane-4-carboxylate is used as a pharmaceutical intermediate for the synthesis of various drugs. Its unique structure and properties may contribute to the development of new therapeutic agents with specific biological activities.
Used in Agrochemical Industry:
Ethyl (1R,4S,6S)-7-oxabicyclo[4.1.0]heptane-4-carboxylate is used as an agrochemical intermediate for the production of pesticides or other crop protection agents. Its specific structure may provide novel modes of action or improved efficacy in controlling pests and diseases in agriculture.
Used in Materials Synthesis:
Ethyl (1R,4S,6S)-7-oxabicyclo[4.1.0]heptane-4-carboxylate is used as a building block in the synthesis of advanced materials, such as polymers, coatings, or adhesives. Its unique structure may impart desirable properties to these materials, enhancing their performance in various applications.
Further research and analysis are required to fully understand and harness the potential of ethyl (1R,4S,6S)-7-oxabicyclo[4.1.0]heptane-4-carboxylate in these and other applications. Its complex and specific structure may offer new opportunities for innovation and development in various industries.

Check Digit Verification of cas no

The CAS Registry Mumber 365997-31-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,6,5,9,9 and 7 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 365997-31:
(8*3)+(7*6)+(6*5)+(5*9)+(4*9)+(3*7)+(2*3)+(1*1)=205
205 % 10 = 5
So 365997-31-5 is a valid CAS Registry Number.

365997-31-5SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 15, 2017

Revision Date: Aug 15, 2017

1.Identification

1.1 GHS Product identifier

Product name ethyl (1R,4S,6S)-7-oxabicyclo[4.1.0]heptane-4-carboxylate

1.2 Other means of identification

Product number -
Other names D-1332

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:365997-31-5 SDS

365997-31-5Relevant articles and documents

Preparation method of edoxaban tosylate and isomers thereof

-

Paragraph 0071; 0079-0080, (2021/02/06)

The invention discloses a preparation method of edoxaban tosylate and isomers thereof. By taking a compound (I) and a compound (II) as starting materials, the method can be used to prepare any one ofhigh-purity edoxaban tosylate (1S, 2R, 4S), edoxaban tosylate enantiomers (1R, 2S, 4R), edoxaban tosylate epimers (1R, 2R, 4S) and edoxaban tosylate epimers (1S, 2S, 4R). Effective guarantee is provided for process research and quality control of the edoxaban tosylate bulk drug and related preparations, the preparation method is suitable for commercialization, the produced edoxaban tosylate bulk drug is high in purity and has great significance and practical value, and the production of the edoxaban tosylate bulk drug and the control of drug quality are facilitated.

Design, synthesis, and biological activity evaluation of a series of pleuromutilin derivatives with novel C14 side chains

Li, Yun-Ge,Wang, Ju-Xian,Wang, Yu-Cheng,You, Xue-Fu,Zhang, Fan,Zhang, Guo-Ning,Zhu, Mei

, (2020/02/11)

In this work, according to the ‘me-too me-better’ design strategy, a peculiar side chain different from lefamulin at C14 position of pleuromutilin was introduced. A series of novel thioether pleuromutilin derivatives containing cyclohexane in the C14 chain was synthesized by ten-step synthesis reaction. All derivatives were characterized by Nuclear Magnetic Resonance (NMR) and High Resolution Mass Spectrometer (HRMS). Furthermore, majority of derivatives displayed moderate antibacterial activity in vitro. However, the compound 2C and 2J exhibited comparable or superior antibacterial activity to lefamulin. The summarized structure-activity relationship not only made the variety of pleuromutilin derivatives more diverse, but also provided new ideas for its design and development.

SALT OF AMINE-PROTECTED (1S,2R,4S)-1,2-AMINO-N,N-DIMETHYLCYCLOHEXANE-4-CARBOXAMIDE

-

Page/Page column 21, (2018/02/20)

Disclosed are compounds and methods for the preparation of Edoxaban. In particular, a camphor sulfonate salt of an amine-protected [(1R,2S,5S)-1,2-amino-5-[(dimethylamino)carbonyl] cyclohexane, an intermediate that may be formed in the synthesis of Edoxaban, is disclosed as well as methods of its preparation.

An efficient stereoselective synthesis of six stereoisomers of 3, 4-diaminocyclohexane carboxamide as key intermediates for the synthesis of factor Xa inhibitors

Wang, Xin,Ma, Mingliang,Reddy, Alavala Gopi Krishna,Hu, Wenhao

, p. 1381 - 1388 (2017/02/18)

An efficient stereoselective route for the preparation of six stereoisomers of tert-butyl ((1R, 2S, 5S)-2-amino-5-(dimethylcarbamoyl)cyclohexyl)carbamate 1 starting from simple 3-cyclohexene-1-carboxylic acid has been described. Stereochemistry of the tit

Discovery of N-[(1R,2S,5S)-2-{[(5-chloroindol-2-yl)carbonyl]amino}-5-(dimethylcarbamoyl)cyclohexyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide hydrochloride: A novel, potent and orally active direct inhibitor of factor Xa

Nagata, Tsutomu,Yoshino, Toshiharu,Haginoya, Noriyasu,Yoshikawa, Kenji,Nagamochi, Masatoshi,Kobayashi, Syozo,Komoriya, Satoshi,Yokomizo, Aki,Muto, Ryo,Yamaguchi, Mitsuhiro,Osanai, Ken,Suzuki, Makoto,Kanno, Hideyuki

experimental part, p. 1193 - 1206 (2009/08/08)

In the early 1990's, we reported on the low-molecular selective fXa inhibitor DX-9065a having two amidino groups. However, it had poor oral bioavailability due to its strong basic amidino groups. To obtain fXa inhibitors with improved oral bioavailability

DIAMINE DERIVATIVES

-

Page/Page column 192-193, (2008/06/13)

A compound represented by formula (1):Q1-Q2-To-N(R1) -Q3-N(R2)-T1-Q4 [wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 represents the following group: (wherein Q5 is an alkylene group having 1 to 8 carbon atoms, or the like); and T0 and T1 are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

Diamine derivatives

-

, (2008/06/13)

A compound represented by the general formula (1): Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4??(1) wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

DIAMINE DERIVATIVES

-

Page 105, (2008/06/13)

A compound represented by the general formula (1):Q1-Q2-T0-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 are hydrogen atoms or the like; Q1 is a saturated or unsaturated, 5- or 6- membered cyclic hydrocarbon group which may be substituted, or the like; Q2 is a single bond or the like; Q3 is a group in which Q5 is an alkylene group having 1 to 8 carbon atoms, or the like; and T0 and T1 are carbonyl groups or the like; a salt thereof, a solvate thereof, or an N-oxide thereof. The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

ETHYLENEDIAMINE DERIVATIVES

-

, (2008/06/13)

The invention relates a compound represented by the formula (1):Q1-Q2-C(=O)-N(R1)-Q3-N(R2)-T1-Q4 wherein R1 and R2 represent H or the like; Q1 represents an aromatic ring, heterocyclic ring or the like; Q2 represents a single bond, aromatic ring, heterocyclic ring or the like; Q3 represents a group or the like, Q4 represents an aromatic ring, heterocyclic ring or the like; and T1 represents -CO- or -SO2-, and a medicine which comprises the compound and is useful for thrombosis and embolism.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 365997-31-5